|
1
|
Ahmed A: DEFi - Heart Failure: A guide to
management of geriatric heart failure by generalist physicians.
Minerva Med. 100:39–50. 2009.PubMed/NCBI
|
|
2
|
Mozaffarian D, Benjamin EJ, Go AS, Arnett
DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP,
Fullerton HJ, et al Writing Group Members; American Heart
Association Statistics Committee; Stroke Statistics Subcommittee, :
Heart disease and stroke statistics- 2016 update: A report from the
American Heart Association. Circulation. 133:e38–e360. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heidenreich PA, Albert NM, Allen LA,
Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam
MA, Maddox TM, et al: American Heart Association Advocacy
Coordinating Committee; Council on Arteriosclerosis, Thrombosis and
Vascular Biology; Council on Cardiovascular Radiology and
Intervention; Council on Clinical Cardiology; Council on
Epidemiology and Prevention; Stroke Council: Forecasting the impact
of heart failure in the United States: A policy statement from the
American Heart Association. Circ Heart Fail. 6:606–619. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lloyd-Jones DM, Larson MG, Leip EP, Beiser
A, D'Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ and
Levy D; Framingham Heart Study, : Lifetime risk for developing
congestive heart failure: The Framingham Heart Study. Circulation.
106:3068–3072. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mureddu GF, Agabiti N, Rizzello V,
Forastiere F, Latini R, Cesaroni G, Masson S, Cacciatore G,
Colivicchi F, Uguccioni M, et al PREDICTOR Study Group, :
Prevalence of preclinical and clinical heart failure in the
elderly. A population-based study in Central Italy. Eur J Heart
Fail. 14:718–729. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schocken DD, Benjamin EJ, Fonarow GC,
Krumholz HM, Levy D, Mensah GA, Narula J, Shor ES, Young JB and
Hong Y; American Heart Association Council on Epidemiology and
Prevention; American Heart Association Council on Clinical
Cardiology; American Heart Association Council on Cardiovascular
Nursing; American Heart Association Council on High Blood Pressure
Research; Quality of Care and Outcomes Research Interdisciplinary
Working Group and Functional Genomics and Translational Biology
Interdisciplinary Working Group, : Prevention of heart failure: A
scientific statement from the American Heart Association Councils
on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular
Nursing, and High Blood Pressure Research; Quality of Care and
Outcomes Research Interdisciplinary Working Group; and Functional
Genomics and Translational Biology Interdisciplinary Working Group.
Circulation. 117:2544–2565. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Morrow DA and O'Donoghue ML: Galectin-3 in
cardiovascular disease: A possible window into early myocardial
fibrosis. J Am Coll Cardiol. 60:1257–1258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sharma UC, Pokharel S, van Brakel TJ, van
Berlo JH, Cleutjens JP, Schroen B, André S, Crijns HJ, Gabius HJ,
Maessen J, et al: Galectin-3 marks activated macrophages in
failure-prone hypertrophied hearts and contributes to cardiac
dysfunction. Circulation. 110:3121–3128. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ho JE, Liu C, Lyass A, Courchesne P,
Pencina MJ, Vasan RS, Larson MG and Levy D: Galectin-3, a marker of
cardiac fibrosis, predicts incident heart failure in the community.
J Am Coll Cardiol. 60:1249–1256. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rabinovich GA, Liu FT, Hirashima M and
Anderson A: An emerging role for galectins in tuning the immune
response: Lessons from experimental models of inflammatory disease,
autoimmunity and cancer. Scand J Immunol. 66:143–158. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
van Almen GC, Verhesen W, van Leeuwen RE,
van de Vrie M, Eurlings C, Schellings MW, Swinnen M, Cleutjens JP,
van Zandvoort MA, Heymans S, et al: MicroRNA-18 and microRNA-19
regulate CTGF and TSP-1 expression in age-related heart failure.
Aging Cell. 10:769–779. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B,
Zhang Y, Xu C, Bai Y, Wang H, et al: The muscle-specific microRNA
miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1
and KCNJ2. Nat Med. 13:486–491. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vegter EL, van der Meer P, de Windt LJ,
Pinto YM and Voors AA: MicroRNAs in heart failure: From biomarker
to target for therapy. Eur J Heart Fail. 18:457–468. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lawrie CH, Gal S, Dunlop HM, Pushkaran B,
Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J,
Wainscoat JS, et al: Detection of elevated levels of
tumour-associated microRNAs in serum of patients with diffuse large
B-cell lymphoma. Br J Haematol. 141:672–675. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tijsen AJ, Creemers EE, Moerland PD, de
Windt LJ, van der Wal AC, Kok WE and Pinto YM: MiR423-5p as a
circulating biomarker for heart failure. Circ Res. 106:1035–1039.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
van Rooij E, Sutherland LB, Liu N,
Williams AH, McAnally J, Gerard RD, Richardson JA and Olson EN: A
signature pattern of stress-responsive microRNAs that can evoke
cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA.
103:18255–18260. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Anguita M, Comin J, Almenar L, Crespo M,
Delgado J, Gonzalez-Costello J, Hernandez-Madrid A, Manito N, Perez
de la Sota E, Segovia J, et al: Comments on the ESC Guidelines for
the diagnosis and treatment of acute and chronic heart failure
2012. A report of the Task Force of the Clinical Practice
Guidelines Committee of the Spanish Society of Cardiology. Rev Esp
Cardiol (Engl Ed). 65:874–878. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yancy CW, Jessup M, Bozkurt B, Butler J,
casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi
JL, et al: 2013 ACCF/AHA guideline for the management of heart
failure: A report of the American College of Cardiology
Foundation/American Heart Association Task Force on practice
guidelines. Circulation. 128:240–327. 2013. View Article : Google Scholar
|
|
20
|
Oikonomou E, Tousoulis D, Siasos G,
Zaromitidou M, Papavassiliou AG and Stefanadis C: The role of
inflammation in heart failure: New therapeutic approaches. Hellenic
J Cardiol. 52:30–40. 2011.PubMed/NCBI
|
|
21
|
Bagnall RD, Tsoutsman T, Shephard RE,
Ritchie W and Semsarian C: Global microRNA profiling of the mouse
ventricles during development of severe hypertrophic cardiomyopathy
and heart failure. PLoS One. 7:e447442012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hrynchyshyn N, Jourdain P, Desnos M,
Diebold B and Funck F: Galectin-3: A new biomarker for the
diagnosis, analysis and prognosis of acute and chronic heart
failure. Arch Cardiovasc Dis. 106:541–546. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
de Boer RA, Lok DJ, Jaarsma T, van der
Meer P, Voors AA, Hillege HL and van Veldhuisen DJ: Predictive
value of plasma galectin-3 levels in heart failure with reduced and
preserved ejection fraction. Ann Med. 43:60–68. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dong S, Cheng Y, Yang J, Li J, Liu X, Wang
X, Wang D, Krall TJ, Delphin ES and Zhang C: MicroRNA expression
signature and the role of microRNA-21 in the early phase of acute
myocardial infarction. J Biol Chem. 284:29514–29525. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lv G, Shao S, Dong H, Bian X, Yang X and
Dong S: MicroRNA-214 protects cardiac myocytes against
H2O2-induced injury. J Cell Biochem.
115:93–101. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu L, Ruifrok WP, Meissner M, Bos EM, van
Goor H, Sanjabi B, van der Harst P, Pitt B, Goldstein IJ, Koerts
JA, et al: Genetic and pharmacological inhibition of galectin-3
prevents cardiac remodeling by interfering with myocardial
fibrogenesis. Circ Heartai1. 6:107–117. 2013.
|
|
29
|
Martínez-Martínez E, Calvier L,
Fernández-Celis A, Rousseau E, Jurado-López R, Rossoni LV, Jaisser
F, Zannad F, Rossignol P, Cachofeiro V, et al: Galectin-3 blockade
inhibits cardiac inflammation and fibrosis in experimental
hyperaldosteronism and hypertension. Hypertension. 66:767–775.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Duan Q, Yang L, Gong W, Chaugai S, Wang F,
Chen C, Wang P, Zou MH and Wang DW: MicroRNA-214 is upregulated in
heart failure patients and suppresses XBP1-mediated endothelial
cells angiogenesis. J Cell Physiol. 230:1964–1973. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sun M, Yu H, Zhang Y, Li Z and Gao W:
MicroRNA-214 mediates isoproterenol-induced proliferation and
collagen synthesis in cardiac fibroblasts. Sci Rep. 5:183512015.
View Article : Google Scholar : PubMed/NCBI
|
